Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19. This can be found at the link,’Antib…
-
Business24 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News10 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General24 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News18 hours agoCountdown on for Noosa Eat & Drink Festival 2025